Form 4: Regeneron EVP Andrew Murphy Executes Stock Option and Sells Shares Under 10b5-1 Plan

Regeneron's EVP of Research, Andrew Murphy, exercised stock options and sold shares of common stock on March 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, exercised stock options to acquire 20,000 shares of common stock on March 13, 2024, at a price of $399.66 per share.
• On the same day, Murphy disposed of 14,217 shares to cover tax obligations at a price of $971.82.
• Over the course of March 14, 2024, Murphy sold a total of 5,544 shares of Regeneron common stock in multiple transactions at prices ranging from $951.92 to $968.38 per share.
• These transactions were executed under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was adopted on May 9, 2023.
• Following these transactions, Murphy directly owns 48,597 shares of common stock and indirectly owns 4,310 shares through a 401(k) plan.
• He also continues to hold options for 20,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often related to compensation and personal financial planning. The use of 10b5-1 plans is a standard practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• Trading activity by executives is closely monitored and must comply with SEC regulations, including the filing of Form 4 within two business days of a transaction.
• The use of 10b5-1 plans is a common practice among executives at companies like Amgen, Gilead Sciences, and Pfizer to manage their stock holdings in a compliant manner.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small volume of shares sold.

Key Dates